Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
60.57
-0.98 (-1.59%)
At close: Oct 28, 2026, 4:00 PM EDT
61.94
+1.37 (2.26%)
After-hours: Oct 28, 2026, 7:56 PM EDT
BMY Revenue
Bristol-Myers Squibb Company had revenue of $12.97B in the quarter ending June 30, 2026, with 5.74% growth. This brings the company's total for the last twelve months to $49.19B, up 3.11% year-over-year. In the year 2025, Bristol-Myers Squibb Company had annual revenue of $48.19B, down -0.22%. That makes Bristol-Myers Squibb Company the 261st largest company in the world by revenue and 96th in the United States.
Revenue (ttm)
$49.19B
Revenue Growth
+3.11%
P/S Ratio
2.52
Revenue / Employee
$1,513,415
Employees
32,500
Market Cap
123.73B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full BMY breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.19B | -106.00M | -0.22% |
| Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
| Dec 31, 2019 | 26.15B | 3.58B | 15.89% |
| Dec 31, 2018 | 22.56B | 1.79B | 8.59% |
| Dec 31, 2017 | 20.78B | 1.35B | 6.94% |
| Dec 31, 2016 | 19.43B | 2.87B | 17.31% |
| Dec 31, 2015 | 16.56B | 681.00M | 4.29% |
| Dec 31, 2014 | 15.88B | -506.00M | -3.09% |
| Dec 31, 2013 | 16.39B | -1.24B | -7.01% |
| Dec 31, 2012 | 17.62B | -3.62B | -17.05% |
| Dec 31, 2011 | 21.24B | 1.76B | 9.03% |
| Dec 31, 2010 | 19.48B | 676.00M | 3.59% |
| Dec 31, 2009 | 18.81B | 1.09B | 6.17% |
| Dec 31, 2008 | 17.72B | 2.10B | 13.43% |
| Dec 31, 2007 | 15.62B | -591.00M | -3.65% |
| Dec 31, 2006 | 16.21B | -2.40B | -12.88% |
| Dec 31, 2005 | 18.61B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 66.57B |
| AbbVie | 64.39B |
| Pfizer | 63.70B |
| AstraZeneca | 61.37B |
| Novartis AG | 57.36B |
| Sanofi | 55.89B |
| Novo Nordisk | 50.34B |
| GSK plc | 44.05B |
BMY News
- 2 days ago - Bristol Myers price target lowered to $78 from $82 at Piper Sandler - TheFly
- 2 days ago - Bristol Myers, SystImmune announce results from Phase 3 study of iza-bren - TheFly
- 2 days ago - Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study - Business Wire
- 3 days ago - BioNTech, Bristol Myers announces data from Phase 2 ROSETTA Lung-107 trial - TheFly
- 5 days ago - Bristol Myers tells Bloomberg aims to resume paused CAR-T trials in 2027 - TheFly
- 5 days ago - Bristol Myers discloses death of CAR T patient in MS study - TheFly
- 5 days ago - Bristol Myers presents results from Phase 1 Breakfree-2 study - TheFly
- 5 days ago - Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026 - Business Wire